On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.

Anning Xiong,Jianlin Xu,Shuyuan Wang,Runbo Zhong,Jun Lu,Tianqing Chu,Wei Zhang,Ying Li,Xiaoxuan Zheng,Baohui Han,Wei Nie,Hua Zhong,Xueyan Zhang

Frontiers in immunology（2023）

引用 0|浏览5

暂无评分

摘要

Continuous assessment of LIPI might be an effective method for predicting the efficacy of PD-1 inhibitor plus chemotherapy in NSCLC patients. In addition, in patients with the negative or low PD-L1 expression level, it might also have a potential predictive value for therapeutic efficacy to continuously assess LIPI during the treatment.

查看译文

关键词

cell lung cancer,lung cancer,immune prognostic index,chemotherapy,on-treatment,first-line,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要